Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2002

View Archived Issues

Use of Apligraf in the treatment of full thickness wounds

Hyaluronic acid-based therapeutic for hereditary pulmonary disorder safe in early clinical trial

Radiopharmaceutical from TransMolecular cleared for testing in humans

Preclinical data provide rationale for phase III evaluation of exisulind/docetaxel in NSCLC

Involvement of tachykininergic and cholinergic pathways in the prokinetic effects of ML-10302

Losartan superior to atenolol in reducing cardiovascular events in LIFE trial

AJW-200 exerts a sustained antiplatelet effect without excessive bleeding in primates

Novel antidiabetic tetrazolylphenylacetamides described in recent patent

Compounds for autoimmune diseases under study at Mitsubishi Pharma

Heterocyclic compounds useful in obesity and diabetes according to Shionogi patent

Naturally produced telomerase inhibitor identified by Japanese scientists

Kyowa Hakko team designs new inhibitors of adenosine uptake

Antibacterial nocathiacin derivatives in development at BMS

Novel compounds patented by Brigham & Women's for use in Alzheimer's disease

Treatment initiated in at-home phase II/III trial of Alista for FSAD

Guidant licenses everolimus from Novartis for use in drug-eluting stents

AstraZeneca returns rights, preclinical data for RSD-1122

Chiron completes acquisition of Matrix

LifeTECH changes name to IATRA Life Sciences

Combinations of morphine, clonidine and cholinesterase inhibitors examined in rat formalin test

Paxil CR launch date set

Multiple breast cancer suppressive activities for pomegranate (Punica granatum) fractions

Phase I ADL-10-0101 program expanded

New Thai study of Remune in HIV to broaden use

Stannsoporfin cleared to enter phase III trial for prevention of hyperbilirubinemia

Interneuron renamed Indevus Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...